Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference
DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14 – 16, 2020.
In addition, management will be participating in one-on-one meetings with investors who are registered to attend the conference.
Exhibit Hall Grand Opening Reception - Hall D
Time: 5:00-7:00 pm
Real-time Insights: A Case Study for the Next Generation of Smart Construction Ecosystem